BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 30667319)

  • 1. Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.
    Barbosa BC; Marchiori E; Leal Leidersnaider C; Brandao L; Castillo M
    Neuroradiol J; 2019 Apr; 32(2):103-107. PubMed ID: 30667319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining Diffusion Tensor Metrics and DSC Perfusion Imaging: Can It Improve the Diagnostic Accuracy in Differentiating Tumefactive Demyelination from High-Grade Glioma?
    Hiremath SB; Muraleedharan A; Kumar S; Nagesh C; Kesavadas C; Abraham M; Kapilamoorthy TR; Thomas B
    AJNR Am J Neuroradiol; 2017 Apr; 38(4):685-690. PubMed ID: 28209583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Findings in Tumefactive Demyelinating Lesions: A Systematic Review and Meta-Analysis.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    AJNR Am J Neuroradiol; 2018 Sep; 39(9):1643-1649. PubMed ID: 30115676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms.
    Mabray MC; Cohen BA; Villanueva-Meyer JE; Valles FE; Barajas RF; Rubenstein JL; Cha S
    AJR Am J Roentgenol; 2015 Nov; 205(5):1075-85. PubMed ID: 26496556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and imaging correlation in patients with pathologically confirmed tumefactive demyelinating lesions.
    Tremblay MA; Villanueva-Meyer JE; Cha S; Tihan T; Gelfand JM
    J Neurol Sci; 2017 Oct; 381():83-87. PubMed ID: 28991721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional and advanced magnetic resonance imaging in tumefactive demyelination.
    Saini J; Chatterjee S; Thomas B; Kesavadas C
    Acta Radiol; 2011 Dec; 52(10):1159-68. PubMed ID: 22025739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumefactive demyelinating lesion: experience with two unusual patients.
    Sinha MK; Garg RK; Bhatt ML; Chandra A
    J Postgrad Med; 2010; 56(2):146-9. PubMed ID: 20622396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT?
    Jain R; Ellika S; Lehman NL; Scarpace L; Schultz LR; Rock JP; Rosenblum M; Mikkelsen T
    J Neurooncol; 2010 May; 97(3):383-8. PubMed ID: 19830525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary tumefactive demyelinating lesions in children.
    Morin MP; Patenaude Y; Sinsky AB; Banwell B; Sébire G
    J Child Neurol; 2011 Aug; 26(8):995-9. PubMed ID: 21555780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of Fulminant Demyelinating Disorders of the Central Nervous System.
    Razek AAKA; Elsebaie NA
    J Comput Assist Tomogr; 2020; 44(2):248-254. PubMed ID: 32195804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and magnetic resonance imaging (MRI) distinctions between tumefactive demyelination and brain tumors in children.
    Yiu EM; Laughlin S; Verhey LH; Banwell BL;
    J Child Neurol; 2014 May; 29(5):654-65. PubMed ID: 24092896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumefactive demyelinating lesions.
    Dagher AP; Smirniotopoulos J
    Neuroradiology; 1996 Aug; 38(6):560-5. PubMed ID: 8880719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demyelination preceding a diagnosis of central nervous system lymphoma.
    Kalus S; Di Muzio B; Gaillard F
    J Clin Neurosci; 2016 Feb; 24():146-8. PubMed ID: 26455545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas.
    Ikeguchi R; Shimizu Y; Abe K; Shimizu S; Maruyama T; Nitta M; Abe K; Kawamata T; Kitagawa K
    Mult Scler Relat Disord; 2018 Nov; 26():77-84. PubMed ID: 30237108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo evolution of biopsy-proven inflammatory demyelination quantified by R2t* mapping.
    Xiang B; Wen J; Lu HC; Schmidt RE; Yablonskiy DA; Cross AH
    Ann Clin Transl Neurol; 2020 Jun; 7(6):1055-1060. PubMed ID: 32367692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging.
    Enzinger C; Strasser-Fuchs S; Ropele S; Kapeller P; Kleinert R; Fazekas F
    Mult Scler; 2005 Apr; 11(2):135-9. PubMed ID: 15794384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging features of solitary inflammatory brain masses.
    Bakshi R; Glass J; Louis DN; Hochberg FH
    J Neuroimaging; 1998 Jan; 8(1):8-14. PubMed ID: 9442584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló's concentric sclerosis.
    Hardy TA; Tobin WO; Lucchinetti CF
    Mult Scler; 2016 Jul; 22(8):986-92. PubMed ID: 27037180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perfusion Imaging of Tumefactive Demyelinating Lesions Compared to High Grade Gliomas.
    Parks NE; Bhan V; Shankar JJ
    Can J Neurol Sci; 2016 Mar; 43(2):316-8. PubMed ID: 26573406
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.